SCHEMBL560756

SCHEMBL560756

COc1cccc(Oc2cnc(N)c(-c3nc4ccccc4[nH]3)n2)c1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ATR Q13535 11/20 0.52
ALDH1A1 P00352 4/20 0.49
SMN1; SMN2 Q16637 3/20 0.49
NPC1 O15118 3/20 0.49
RAB9A P51151 3/20 0.49
TP53 P04637 2/20 0.49
MEN1 O00255 3/20 0.48
KMT2A Q03164 3/20 0.48
GAA P10253 1/20 0.48
MAPT P10636 1/20 0.48
TDP1 Q9NUW8 1/20 0.48
PRKDC P78527 1/20 0.47
ATM Q13315 1/20 0.47
SLC2A1 P11166 1/20 0.47
KDM4E B2RXH2 2/20 0.46
PKM P14618 2/20 0.46
BRCA1 P38398 1/20 0.45
HBB P68871 1/20 0.45
HSD17B10 Q99714 1/20 0.45
FGFR1 P11362 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL560535 0.89 ATR (0.52) ATRALDH1A1SMN1; SMN2MEN1KMT2A
SCHEMBL559766 0.87 ATR (0.63) ATRALDH1A1SMN1; SMN2NPC1RAB9A
SCHEMBL560116 0.87 CYP1A2 (0.56) ATRALDH1A1SMN1; SMN2NPC1RAB9A
SCHEMBL560088 0.84 ATR (0.59) ATRALDH1A1SMN1; SMN2PRKDCATM
SCHEMBL560151 0.82 KMT2A (0.56) ATRALDH1A1SMN1; SMN2NPC1RAB9A
SCHEMBL560058 0.82 ATR (0.64) ATRALDH1A1SMN1; SMN2PRKDCATM
SCHEMBL560062 0.82 ATR (0.49) ATRALDH1A1SMN1; SMN2NPC1RAB9A
SCHEMBL10165965 0.80 ATR (0.52) ATRALDH1A1SMN1; SMN2NPC1RAB9A
SCHEMBL560098 0.79 ATR (0.53) ATRALDH1A1SMN1; SMN2NPC1RAB9A
SCHEMBL561015 0.78 ATR (0.52) ATRALDH1A1SMN1; SMN2NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8962631-B2 Compounds useful as inhibitors of ATR kinase VERTEX PHARMACEUTICALS INCORPORATED (US) 2015-02-24 US disclosed
US-8962631-B2 Compounds useful as inhibitors of ATR kinase VERTEX PHARMACEUTICALS INCORPORATED (US) 2015-02-24 US disclosed
US-8962631-B2 Compounds useful as inhibitors of ATR kinase VERTEX PHARMACEUTICALS INCORPORATED (US) 2015-02-24 US disclosed
EP-2569289-A1 PYRAZINES USEFUL AS INHIBITORS OF ATR KINASE Vertex Pharmaceuticals Incorporated (US) 2013-03-20 EP disclosed
US-20120035407-A1 COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-02-09 US disclosed
US-20120035407-A1 COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-02-09 US disclosed
US-20120035407-A1 COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-02-09 US disclosed
WO-2011143419-A1 PYRAZINES USEFUL AS INHIBITORS OF ATR KINASE VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-11-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120035407-A1 COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE ATR, CHEK1, CHEK2 ATR 1/4885ALDH1A1 4062/4885SMN1; SMN2 1678/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.